Cargando…

Safety and efficacy of varicella vaccination in children with JIA treated with biologic therapy

Detalles Bibliográficos
Autores principales:	Toplak, Natasa, Avcin, Tadej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184138/ http://dx.doi.org/10.1186/1546-0096-12-S1-O20

Ejemplares similares

The effects of early aggressive therapy in JIA: results of the TREAT study
por: Wallace, Carol A, et al.
Publicado: (2012)

MEFV and NLRP3 gene variants in children with pfapa syndrome in slovenia
por: Perko, Daša, et al.
Publicado: (2014)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNFα drugs early in disease course
por: Ključevšek, Damjana, et al.
Publicado: (2017)

Genetic determinants of methotrexate treatment efficacy in patients with juvenile idiopathic arthritis
por: Avramovič, Mojca Zajc, et al.
Publicado: (2014)

4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
por: Hinze, CH, et al.
Publicado: (2008)

To evaluate the impact of a nurse-led JIA education program on parental satisfaction regarding knowledge of JIA and its management
por: Jones, J, et al.
Publicado: (2011)

Histone antibodies as a biomarker of uveitis in JIA
por: Nordal, Ellen B, et al.
Publicado: (2014)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

PReS-FINAL-2177: Safety and lack of autoantibody production following influenza H1N1 vaccination in patients with juvenile idiopathic arthritis (JIA)
por: Aikawa, N, et al.
Publicado: (2013)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Acute respiratory infections, influenza-like illness and JIA: impact on disease activity and response to the influenza vaccine
por: Carvalho, Luciana M, et al.
Publicado: (2012)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

Serious infections in JIA patients upon MTX, TFN inhibitors and combinations
por: Horneff, Gerd, et al.
Publicado: (2014)

The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives
por: Toplak, Nataša, et al.
Publicado: (2018)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Virtual 3D/4D vascular sonobiopsy of the knee joint: validation of the method in the JIA patients treated with ia infliximab or triamcinolone hexacetonide
por: Harjacek, Miroslav, et al.
Publicado: (2014)

Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
por: Moncrieffe, H, et al.
Publicado: (2011)

Disease relapse rate in children with autoimmune rheumatic diseases after COVID-19 infection and vaccination
por: Šinkovec Savšek, Tjaša, et al.
Publicado: (2023)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

MRI and ultrasound versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in JIA. Do these imaging techniques have an additional value?
por: Malattia, C, et al.
Publicado: (2011)

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate
por: Ursu, S, et al.
Publicado: (2011)

Autoimmune response following influenza vaccination
por: Toplak, N, et al.
Publicado: (2008)

OA30 Genetic analysis of whole exome sequencing in a cohort of children with refractory JIA reveals genetic risk factors for rare juvenile diseases
por: Tordoff, Melissa, et al.
Publicado: (2022)

Clinical Features and Genetic Background of the Periodic Fever Syndrome with Aphthous Stomatitis, Pharyngitis, and Adenitis: A Single Center Longitudinal Study of 81 Patients
por: Perko, Daša, et al.
Publicado: (2015)

Understanding the biology and use of TNF therapy in jia-clinical outcomes
por: Lovell, Daniel, et al.
Publicado: (2014)

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
por: de Jager, W, et al.
Publicado: (2011)

The response to hepatitis a vaccine in children with JIA on immunosuppresive treatment
por: Maritsi, Despoina, et al.
Publicado: (2014)

Periodic fever syndrome with aphthous stomatitis, pharyngitis and cervical adenopathy treated with ketotifen – a case report
por: Toplak, N, et al.
Publicado: (2008)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH
por: Holzinger, D, et al.
Publicado: (2015)

14.1 Clinical spectrum and outcome in 100 children with positive antiphospholipid antibodies
por: Rozic, M, et al.
Publicado: (2008)

Regulatory T cells from the inflamed joints of patients with juvenile idiopathic arthritis (JIA) are dysregulated and display a pro-inflammatory profile
por: Pesenacker, AM, et al.
Publicado: (2011)

Varicella immunity and vaccine response in children with juvenile idiopathic arthritis treated with DMARD
por: Boldingh, AM, et al.
Publicado: (2011)

Low levels of the nerve growth factor receptor TrkA in JIA: a possible defect in a novel anti-inflammatory mechanism
por: Minnone, G, et al.
Publicado: (2011)

PReS-FINAL-2314: Anti-TNF alpha therapy for refractory childhood takayasu arthritis
por: Koren, B, et al.
Publicado: (2013)

Performance of IFN-Gamma release assays for detection of tuberculosis infection in juvenile I JIA children in biological therapy
por: Assante, L, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_52kq310c3gobucccjib0rjras8